Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 11Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia 1

Interventions

venetoclax 77Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 45Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23Decitabine 22obinutuzumab 21Etoposide 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Injections 15Doxorubicin 15pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Epoetin Alfa × Other hematologic neoplasm × Clear all
NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡